These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22365247)

  • 21. [The expressions and meanings of BMP-7 and TGF-β in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia].
    Gu P; Luo B; Yi X; Zhu H; Li S; Yu X; Han F; Zhang S; Zhu X; Rui W; Qiu W; Fan D
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Sep; 37(9):664-70. PubMed ID: 25533688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors.
    Farkas L; Gauldie J; Voelkel NF; Kolb M
    Am J Respir Cell Mol Biol; 2011 Jul; 45(1):1-15. PubMed ID: 21057104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP).
    Kiszałkiewicz J; Piotrowski W; Brzeziańska-Lasota E
    Adv Respir Med; 2017; 85(3):169-178. PubMed ID: 28667660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises.
    Spagnolo P; Tzouvelekis A; Maher TM
    Curr Opin Pulm Med; 2015 Sep; 21(5):470-8. PubMed ID: 26132817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Putting the brakes on age-related idiopathic pulmonary fibrosis: can Nox4 inhibitors suppress IPF?
    Turn CS; Lockey RF; Kolliputi N
    Exp Gerontol; 2015 Mar; 63():81-2. PubMed ID: 25668226
    [No Abstract]   [Full Text] [Related]  

  • 26. [Novel therapies for idiopathic pulmonary fibrosis].
    Wand O; Kremer MR
    Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Yarahmadi R; Ghaznavi H; Mehrzadi S
    Expert Opin Ther Targets; 2018 Dec; 22(12):1049-1061. PubMed ID: 30445883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of transforming growth factor-β signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis.
    Lilja-Maula L; Syrjä P; Laurila HP; Sutinen E; Rönty M; Koli K; Rajamäki MM; Myllärniemi M
    J Comp Pathol; 2014 May; 150(4):399-407. PubMed ID: 24529509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research.
    Baroke E; Gauldie J; Kolb M
    Expert Rev Respir Med; 2013 Oct; 7(5):465-78. PubMed ID: 24138691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for treating idiopathic pulmonary fibrosis.
    du Bois RM
    Nat Rev Drug Discov; 2010 Feb; 9(2):129-40. PubMed ID: 20094055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis.
    Kato K; Hecker L
    Redox Biol; 2020 Jun; 33():101541. PubMed ID: 32360174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel mechanisms and treatment of idiopathic pulmonary fibrosis.
    Elmufdi F; Henke CA; Perlman DM; Tomic R; Kim HJ
    Discov Med; 2015 Sep; 20(109):145-53. PubMed ID: 26463096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic pulmonary fibrosis: an Australian perspective.
    Prasad J; Holland AE; Glaspole I; Westall G
    Intern Med J; 2016 Jun; 46(6):663-8. PubMed ID: 27257148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin.
    Veith C; Drent M; Bast A; van Schooten FJ; Boots AW
    Toxicol Appl Pharmacol; 2017 Dec; 336():40-48. PubMed ID: 28987380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.
    Vaidya B; Patel R; Muth A; Gupta V
    Curr Med Chem; 2017; 24(22):2439-2458. PubMed ID: 28552057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current clinical trials for the treatment of idiopathic pulmonary fibrosis.
    Klingsberg RC; Mutsaers SE; Lasky JA
    Respirology; 2010 Jan; 15(1):19-31. PubMed ID: 20199632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.